We are live on ! Find out more
TRAW icon

Traws Pharma

12 hedge funds and large institutions have $3.8M invested in Traws Pharma in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,048% more capital inflows, than outflows

Capital inflows: $5.15M | Capital outflows: $449K

11.99% less ownership

Funds ownership: 11.99% → 0% (-12%)

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

57% less funds holding

Funds holding: 28 → 12 (-16)

94% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 17

Holders
12
Holders Change
-16
Holders Change %
-57.14%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
4
Reduced
5
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

TRAW Hedge Fund Activity: Q3 2024 in Review

12 of the 6,991 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q3 2024, worth a combined $3.8M — up 180% from $1.36M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of TRAW and 1 opened new positions — a net loss of 16 holders — while 5 trimmed existing stakes and 4 added.

The largest buyer was OrbiMed, adding an estimated $5.13M. The largest seller was Geode Capital Management, exiting entirely with an estimated $100K sold.

  • 12 institutional investors held Traws Pharma (TRAW) as of Q3 2024, down from 28 in Q2 2024.
  • Funds reported $3.8M of Traws Pharma stock for Q3 2024, up 180% quarter-over-quarter.
  • 1 fund opened new Traws Pharma positions in Q3 2024 and 17 closed out, a net change of -16 holders.
  • The largest Traws Pharma buyer in Q3 2024 was OrbiMed, an estimated $5.13M added.
  • The largest Traws Pharma seller in Q3 2024 was Geode Capital Management, an estimated $100K sold.

Based on aggregated 13F filings for Q3 2024.